The correlative circulating tumor DNA (ctDNA) studies of the PALOMA-3 clinical trial showed that acquired resistance to fulvestrant and palbociclib is associated with clonal evolution and acquired mutations in RB1, PIK3CA, and ESR1, with the latter two related to fulvestrant resistance. These results highlight the potential of ctDNA as a tool to detect mechanisms of resistance and infer the next line of treatment. Cancer Discov; 8(11); 1352-4. ©2018 AACR See related article by O'Leary et al., p. 1390.
©2018 American Association for Cancer Research.